How does body weight affect cosentyx level range?

How does body weight change the amount of Cosentyx that stays in the body?

Cosentyx (secukinumab) clearance rises with increasing body weight, so heavier patients reach lower blood concentrations after the same dose. In pharmacokinetic data, clearance values range from about 0.14 L/day at 50 kg to 0.24 L/day at 120 kg, producing steady-state trough levels that can differ by roughly 30–40% across that weight span.

Can higher doses be used for heavier patients?

The approved regimens stay weight-independent: 150 mg or 300 mg given every four weeks after initial weekly loading doses. Regulators did not require weight-based adjustments because the exposure variation remained within acceptable efficacy and safety margins. Some clinicians still consider the 300 mg dose for patients above 90 kg when response is incomplete.

Why do levels matter in practice?

Lower exposure in heavier individuals has been linked to slower onset of skin clearance in plaque psoriasis and modestly reduced joint responses in psoriatic arthritis. Therapeutic drug monitoring is not routine, but clinicians sometimes check levels when a patient loses response or experiences breakthrough flares.

What happens if a patient gains or loses significant weight?

A sustained 10–15 kg change can shift trough concentrations enough to move a patient from the lower to the upper end of the observed range. Dose escalation to 300 mg or shortening the interval to every three weeks has been reported in observational cohorts when weight gain coincides with loss of control.

How do Cosentyx levels compare with other IL-17 inhibitors?

Brodalumab and ixekizumab show similar weight-related clearance increases, although ixekizumab labeling includes an optional 160 mg starting dose for patients above 90 kg. Real-world data suggest that patients above 100 kg more often need dose intensification with any IL-17 agent.

When does Cosentyx patent protection end?

U.S. regulatory exclusivity for the psoriasis indication expires in 2026, with the composition-of-matter patent listed to lapse in 2029. DrugPatentWatch.com tracks ongoing biosimilar filings and any new patents that could extend protection.

[1] DrugPatentWatch.com